ibuprofen and spironolactone

Pharmacodynamic interaction. Ibuprofen inhibits renal prostaglandin synthesis, reducing renal blood flow and glomerular filtration. This decreases the delivery of sodium and water to the distal tubule, blunting the natriuretic and diuretic effect of spironolactone. Both drugs can also raise serum potassium: spironolactone blocks aldosterone receptors, reducing renal potassium excretion, while ibuprofen-induced renal impairment further reduces potassium clearance. The combined effect is an additive risk of hyperkalaemia.

Clinically, ibuprofen can reduce the antihypertensive and diuretic efficacy of spironolactone, leading to worsening hypertension, oedema, or heart failure. More importantly, co-administration increases the risk of hyperkalaemia, particularly in patients with chronic kidney disease, diabetes, or taking other potassium-elevating drugs such as ACE inhibitors or angiotensin receptor blockers. Severe hyperkalaemia may cause cardiac arrhythmias and is potentially fatal.

Avoid concomitant use when possible, especially in patients with renal impairment or risk factors for hyperkalaemia. If co-prescription is necessary, use the lowest effective dose of ibuprofen for the shortest duration. Monitor serum potassium and renal function (creatinine, eGFR) at baseline, within 3 to 5 days of starting therapy, and regularly thereafter. Consider alternative analgesics such as paracetamol. Adjust the spironolactone dose if renal function or potassium changes.

This interaction is well established. Multiple case reports and observational studies document hyperkalaemia and reduced diuretic response with concurrent NSAID and spironolactone use. It is cited in major drug interaction reference sources and in national guidelines for managing heart failure and hypertension. The mechanism is plausible and supported by experimental studies of renal prostaglandin inhibition.